Comparison of utilization, cost, adherence, and hypoglycemia in patients with type 2 diabetes initiating rapid-acting insulin analog with prefilled pen versus vial/syringe

References

• Iqbal N. The burden of type 2 diabetes: strategies to prevent or delay onset. Vasc Health Risk Manag 2007;3:511-20
   PubMedGoogle Scholar
• NIDDK (NIH). National Diabetes Statistics, 2007. Available at: http://diabetes.niddk.nih.gov/DM/PUBS/statistics/#i_people [Last accessed 12 April 2010]
   Google Scholar
• Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27:1047-53
   PubMed Web of Science ®Google Scholar
• Hogan P, Dall T, Nikolov P. Economic costs of diabetes in the US in 2002. Diabetes Care 2003;26:917-32
   PubMed Web of Science ®Google Scholar
• Economic costs of diabetes in the U.S. in 2007. Diabetes Care 2008;31:596-615
   Google Scholar
• Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009;32:193-203
   PubMed Web of Science ®Google Scholar
• Bazzano LA, Lee LJ, Shi L, et al. Safety and efficacy of glargine compared with NPH insulin for the treatment of Type 2 diabetes: a meta-analysis of randomized controlled trials. Diabet Med 2008;25:924-32
   PubMed Web of Science ®Google Scholar
• Riddle MC. Timely initiation of basal insulin. Am J Med 2004;116(Suppl 3A):3S-S
   Google Scholar
• Oglesby AK, Secnik K, Barron J, et al. The association between diabetes related medical costs and glycemic control: a retrospective analysis. Cost Eff Resour Alloc 2006;4:1
   PubMedGoogle Scholar
• Salas M, Hughes D, Zuluaga A, et al. Costs of medication nonadherence in patients with diabetes mellitus: a systematic review and critical analysis of the literature. Value Health 2009;12:915-22
   PubMed Web of Science ®Google Scholar
• Cramer JA. A systematic review of adherence with medications for diabetes. Diabetes Care 2004;27:1218-24
   PubMed Web of Science ®Google Scholar
• Odegard PS, Capoccia K. Medication taking and diabetes: a systematic review of the literature. Diabetes Educ 2007;33:1014-29; discussion 30-1
   PubMed Web of Science ®Google Scholar
• Polonsky WH. Emotional and quality-of-life aspects of diabetes management. Curr Diab Rep 2002;2:153-9
   PubMedGoogle Scholar
• Polonsky WH, Fisher L, Guzman S, et al. Psychological insulin resistance in patients with type 2 diabetes: the scope of the problem. Diabetes Care 2005;28:2543-5
   PubMed Web of Science ®Google Scholar
• Molife C, Lee LJ, Shi L, et al. Assessment of patient-reported outcomes of insulin pen devices versus conventional vial and syringe. Diabetes Technol Ther 2009;11:529-38
   PubMed Web of Science ®Google Scholar
• Baser O, Bouchard J, Deluzio T, et al. Assessment of adherence and healthcare costs of insulin device (FlexPen(R)) versus conventional vial/syringe. Adv Ther 2010;27(2):94-104
   Google Scholar
• Cobden D, Lee WC, Balu S, et al. Health outcomes and economic impact of therapy conversion to a biphasic insulin analog pen among privately insured patients with type 2 diabetes mellitus. Pharmacotherapy 2007;27:948-62
   PubMed Web of Science ®Google Scholar
• Lee WC, Balu S, Cobden D, et al. Medication adherence and the associated health-economic impact among patients with type 2 diabetes mellitus converting to insulin pen therapy: an analysis of third-party managed care claims data. Clin Ther 2006;28:1712-25; discussion 0-1
   PubMed Web of Science ®Google Scholar
• Pawaskar MD, Camacho FT, Anderson RT, et al. Health care costs and medication adherence associated with initiation of insulin pen therapy in Medicaid-enrolled patients with type 2 diabetes: a retrospective database analysis. Clin Ther 2007;29 Spec No: 1294-305
   Google Scholar
• Asghari S, Courteau J, Carpentier AC, et al. Optimal strategy to identify incidence of diagnostic of diabetes using administrative data. BMC Med Res Methodol 2009;9:62
   Google Scholar
• Peterson AM, Nau DP, Cramer JA, et al. A checklist for medication compliance and persistence studies using retrospective databases. Value Health 2007;10:3-12
   PubMed Web of Science ®Google Scholar
• Leslie R, Gwadry-Sridhar F, Thiebaud P, et al. Calculating medication compliance, adherence and persistence in administrative pharmacy claims databases. Pharmaceutical Programming 2008;1:13-19
   Google Scholar
• Karve S, Cleves MA, Helm M, et al. An empirical basis for standardizing adherence measures derived from administrative claims data among diabetic patients. Med Care 2008;46:1125-33
   PubMed Web of Science ®Google Scholar
• Martin BC, Wiley-Exley EK, Richards S, et al. Contrasting measures of adherence with simple drug use, medication switching, and therapeutic duplication. Ann Pharmacother 2009;43:36-44
   PubMed Web of Science ®Google Scholar
• Yeaw J, Benner JS, Walt JG, et al. Comparing adherence and persistence across 6 chronic medication classes. J Manag Care Pharm 2009;15:728-40
   PubMed Web of Science ®Google Scholar
• Ginde AA, Blanc PG, Lieberman RM, et al. Validation of ICD-9-CM coding algorithm for improved identification of hypoglycemia visits. BMC Endocr Disord 2008;8:4
   PubMedGoogle Scholar
• Lee LJ, Anderson J, Foster SA, et al. Predictors of initiating rapid-acting insulin analog using vial/syringe, prefilled pen, and reusable pen devices in patients with type 2 diabetes. J Diabetes Sci Technol 2010;4:547-57
   PubMedGoogle Scholar